Kymera Therapeutics, Inc.KYMR

Kymera Therapeutics is a clinical-stage biotech company trying to turn the science of targeted protein degradation into medicines, but so far the only thing degrading is its cash. The company’s 10-Q for the quarter ending 31 March 2026 shows revenue of $34.4 million, while it posted a net loss of $69.2 million and negative operating cash flow of $88.8 million. The gap between the polished pitch and the plain numbers is so wide that the company’s website might need a disclaimer: “not actual results.”

Kymera’s science is real-its pipeline is focused on validated disease targets where protein degradation is the best or only way to improve care-but the business is still a research engine without a working revenue engine. The company’s “first-in-class” programmes, including a partnership with Sanofi on KT-485, are in mid-stage trials, yet the financials show no revenue from those programmes, only the steady burn of $98.2 million in R&D and the quiet dilution of 97.5 million diluted shares. The website calls it a “differentiated approach,” but the balance sheet calls it a funding gap.

The company’s assets total $1.67 billion at 31 March 2026, but $1.54 billion of that is shareholder equity, meaning the business is broadly a laboratory with a fortress balance sheet. Liabilities are a modest $129.4 million, but the company’s $144.1 million in cash and cash equivalents is enough to keep the lights on for a few quarters, not enough to fund the long clinical runs its science demands. The operating cash burn of $88.8 million in the quarter is the clearest sign that the business model is still running on hope and dilution rather than approvals and sales.

The company’s June 2026 press release confirms the completion of enrolment in the Phase 2b BROADEN2 trial of KT-485, a second-generation IRAK4 degrader prioritised by Sanofi, but the revenue from that programme has not yet appeared in the company’s filings. The gap between the clinical milestone and the commercial milestone is the single biggest risk to the thesis-and the single biggest reason the share count keeps climbing.

The company’s website is a slick showcase of “cutting-edge technologies,” “high unmet need,” and “first-in-class programmes,” but the only thing actually cutting edge is the rate at which the company is burning through its cash. The site features a pipeline focused on validated disease targets where protein degradation is the only or best way to improve care, yet the financials show no revenue from those programmes, only the steady dilution of 97.5 million diluted shares. The company’s “differentiated approach” is being employed to build a pipeline, but the pipeline is still a cost centre, not a revenue centre.

The company’s SEC filings show no revenue from its Sanofi partnership, no revenue from its internal programmes, and no revenue from its “exciting platform.” The only money coming in is from the balance sheet itself, which is being eroded by $98.2 million a quarter in R&D and $88.8 million in operating cash burn. The company’s cash and cash equivalents of $144.1 million at 31 March 2026 is the clearest sign that the business model is still running on hope and dilution rather than approvals and sales.

For context on the company’s science and pipeline, see the official site’s pipeline page and approach page, which describe the company’s focus on validated disease targets and its belief that protein degradation is the only or best way to improve care. The site is a masterclass in biotech buzzword bingo, but the numbers tell a different story.